Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02211872
Recruitment Status : Completed
First Posted : August 8, 2014
Last Update Posted : August 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective of this study was to determine the maximum tolerated dose (MTD) of BI 2536 BS in patients with advanced solid tumours. Secondary objectives were the evaluation of safety, efficacy, and pharmacokinetics of BI 2536 BS

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BI 2536 BS, intravenous Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Study Start Date : August 2004
Actual Primary Completion Date : March 2007

Arm Intervention/treatment
Experimental: Treatment A
BI 2536 BS single rising dose
Drug: BI 2536 BS, intravenous
Experimental: Treatment B
BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
Drug: BI 2536 BS, intravenous



Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) for a single dose of BI 2536 BS [ Time Frame: Up to 16 weeks ]
  2. MTD for single doses of BI 2536 BS on 3 consecutive days [ Time Frame: Up to 16 weeks ]

Secondary Outcome Measures :
  1. Assessment of objective treatment response by tumour measurements [ Time Frame: Up to 1 year ]
    Evaluated according to the response evaluation criteria in solid tumors (RECIST)

  2. Number of patients with adverse events [ Time Frame: Up to 1 year ]
  3. Maximum concentration of BI 2536 BS analyte in plasma (Cmax) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  4. Time from dosing to maximum concentration of BI 2536 BS in plasma (tmax) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  5. Area under the concentration-time curve of BI 2536 BS in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  6. Percentage of the AUC0-∞ that is obtained by extrapolation (%AUC0-tz) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  7. Terminal rate constant in plasma (λz) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  8. Terminal half-life of BI 2536 BS in plasma (t1/2) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  9. Mean residence time of BI 2536 BS in the body after intravenous administration (MRT) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  10. Total clearance of BI 2536 BS in the plasma after intravascular administration (CL) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  11. Apparent volume of distribution during the terminal phase λz following an intravascular dose (Vz) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  12. Apparent volume of distribution at steady state following intravascular administration (Vss) [ Time Frame: Pre-dose, up to 216 hours after drug administration ]
  13. Amount of BI 2536 BS that is eliminated in urine from the time point 0 to time point 24/48 (Ae0-24/48) [ Time Frame: Pre-dose, up to 48 hours after drug administration ]
  14. Fraction of analyte eliminated in urine from time point 0 to time point 24/48 (fe0-24/48) [ Time Frame: Pre-dose, up to 48 hours after drug administration ]
  15. Renal clearance of BI 2536 BS from the time point 0 to time point 24/48 (CLR,0-24/48) [ Time Frame: Pre-dose, up to 48 hours afterdrug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who had failed conventional treatment, or for whom no therapy of proven efficacy exists, or who were not amenable to established forms of treatment
  • Evaluable tumour deposits
  • Age of 18 years or older
  • Life expectancy of at least 6 months
  • Written informed consent consistent with international conference of harmonization (ICH) - good clinical practice (GCP) and local legislation
  • Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ≤ 2
  • And full recovery from all therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

Exclusion Criteria:

  • Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial protocol
  • Pregnancy or breastfeeding
  • Active infectious disease
  • Known brain metastases
  • Second malignancy requiring therapy
  • Absolute neutrophil count less than 1500/mm3
  • Platelet count less than 100 000/mm3
  • Bilirubin greater than 1.5 mg/dL (> 26 μmol/L, international system of units (SI) equivalent)
  • Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
  • Serum creatinine greater than 1.5 mg/dL (> 132 μmol/L, SI unit equivalent)
  • Sexually active women and men who are unwilling to use a medically acceptable method of contraception
  • Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
  • Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial
  • Patients unable to comply with the trial protocol
  • Or active alcohol or drug abuse
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02211872    
Other Study ID Numbers: 1216.1
First Posted: August 8, 2014    Key Record Dates
Last Update Posted: August 8, 2014
Last Verified: August 2014